# Wellcare Prepares to Grow with New Products and New Markets in Its 10th Year

> Celebrating its 10th anniversary, Wellcare—the consumer health brand of İLKO İlaç—is preparing to launch more than 20 new products starting from late 2026 and the first quarter of 2027, while advancing plans to enter the US export market. Aiming to close 2026 with net revenue in the 1 billion TL range, Wellcare’s roadmap was outlined by Mustafa Cem Öncel, Board Member and Deputy General Manager of Sales & Marketing at İLKO İlaç, who stated the brand's goal to become one of the top three companies in the consumer health market by 2030.

Published: 2026-11-17T09:03:00+00:00
Language: en
Categories: [Pharmaceutical Industry](https://chemexworld.com/en/categories/sectors/pharmaceutical-industry-1.md)

Canonical URL:
https://chemexworld.com/en/news/wellcare-prepares-to-grow-with-new-products-and-new-markets-in-its-10th-year

## Content

Founded in 2016, Wellcare continues its growth momentum backed by İLKO İlaç’s over 50 years of industry heritage, R&D capabilities, and manufacturing facilities in Konya with an annual production capacity of 120 million boxes.

### Outpacing the Market by Twofold

In 2025, Wellcare grew by 78% in net revenue and 29% in unit volume, outperforming the broader OTC market, which expanded by 15% in volume and 57% in net value. According to IQVIA data for January–August 2026, the brand achieved 33% growth in unit sales and 87% growth in TL revenue compared to the same period last year—doubling the market growth rate across both metrics.

Commenting on the growth strategy, **Mustafa Cem Öncel, Board Member and Deputy General Manager of Sales & Marketing at İLKO İlaç**, stated:

> “Powered by İLKO İlaç’s more than 50 years of industry experience, we are marking 10 years in consumer health with Wellcare. We are accelerating the above-market growth momentum we achieved in 2025 throughout 2026. We are meeting rising demand for our products with new launches and expanding our portfolio in line with scientific advancements and consumer needs. Our goal is to become one of the top three companies in the consumer health market by 2030. In pursuing this target, we conduct every operation—from R&D and manufacturing to sales and marketing—with pharmaceutical discipline and a commitment to quality.”

![](https://chemexworld.com/storage/uploads/mustafa_cem_oncel.jpg)

### Next Stop in International Expansion: The United States

Already active across markets ranging from Vietnam and the Turkic Republics to the Middle East, the Balkans, and Africa, Wellcare aims to begin commercial operations in the United States—the world’s largest OTC market—via online sales channels toward the end of 2026.

Recalling that İLKO İlaç Production Facilities completed FDA registration processes in 2025, Öncel remarked:

> “While maintaining our domestic growth, we are also expanding our exports. We view this milestone as a strategic step that will pave the way for our export operations across the Americas and global markets. Our goal is to bring this knowledge and manufacturing strength born in Turkey to more people worldwide.”

### €65 Million R&D Investment and a $750 Million Domestic Market

- **R&D and Manufacturing Infrastructure:** Having invested a total of €65 million in R&D since 2009, İLKO İlaç has worked on over 250 projects over the past three years at its R&D center in Ankara and biotechnology R&D center at Teknopark Istanbul. With 24 internationally registered patents, the 100% domestic-capital company employs over 1,000 people and offers a portfolio of more than 210 products and over 100 molecules, exporting to more than 40 countries alongside providing contract manufacturing services for global firms.
- **Turkish Dietary Supplements Market:** Noting that the domestic market reached approximately $750 million in 2025 while annual per capita spending remains below $10, Öncel highlighted that the market is projected to grow by an average of 15% annually in unit volume over the next five years, with domestic manufacturing accounting for over 80% of the market.
